Comorbidities associated with adult asthma: a population-based matched cohort study in Finland.
Adult
Humans
Finland
/ epidemiology
Dermatitis, Atopic
/ complications
Cohort Studies
Nasal Polyps
/ complications
Asthma
/ epidemiology
Comorbidity
Pulmonary Disease, Chronic Obstructive
/ epidemiology
Sinusitis
/ epidemiology
Rhinitis, Allergic
/ complications
Chronic Disease
Gastroesophageal Reflux
/ epidemiology
Pneumonia
/ epidemiology
Diabetes Mellitus
/ epidemiology
Sleep Apnea Syndromes
/ complications
Asthma
Asthma Epidemiology
COPD epidemiology
Clinical Epidemiology
Pulmonary Disease, Chronic Obstructive
Sleep apnoea
Surveys and Questionnaires
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
17
07
2023
accepted:
29
02
2024
medline:
18
3
2024
pubmed:
15
3
2024
entrez:
14
3
2024
Statut:
epublish
Résumé
Asthma is a common chronic disease characterised by variable respiratory symptoms and airflow limitation, affecting roughly 4%-10% of the adult population. Adult asthma is associated with higher all-cause mortality compared to individuals without asthma. In this study, we investigate the comorbidities that may affect the management of asthma. Total of 1648 adults with asthma and 3310 individuals without asthma aged 30-93 were matched with age, gender and area of residency, and followed from 1 January 1997 to 31 December 2013. Baseline information was collected with questionnaires 1997 and follow-up register data from the national discharge registry Finnish Institute for Health and Welfare. Data included diagnoses from outpatient care and day surgery of specialised health care, and data from inpatient care of specialised and primary health care. We included all main diagnoses that had at minimum 200 events and number of diagnoses based on their common appearance with adult asthma. The mean follow-up time varied between 14.2 and 15.1 years, and age at the time of enrolment was 53.9 years for subjects without asthma and 54.4 years for patients with asthma. Chronic obstructive pulmonary disease was 10 times more common among asthmatics. Risk of acute rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis and vocal cord dysfunction was fourfold and risk of pneumonia, and chronic rhinosinusitis was 2.5 times more common among asthmatics. Sleep apnoea, gastro-oesophageal reflux disease, diabetes, allergic rhinitis and dysfunctional breathing were twofold and cataract nearly twofold higher in the asthmatic group. Adult asthma was also significantly associated with musculoskeletal diseases, incontinence and bronchiectasis. The most common and most severe comorbidity of adult asthma in this study was chronic obstructive pulmonary disease. Other common comorbidities of adult asthma include acute rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, allergic rhinitis, dysfunctional breathing, diabetes, pneumonia, sleep apnoea and gastro-oesophageal reflux disease.
Sections du résumé
BACKGROUND
BACKGROUND
Asthma is a common chronic disease characterised by variable respiratory symptoms and airflow limitation, affecting roughly 4%-10% of the adult population. Adult asthma is associated with higher all-cause mortality compared to individuals without asthma. In this study, we investigate the comorbidities that may affect the management of asthma.
METHODS
METHODS
Total of 1648 adults with asthma and 3310 individuals without asthma aged 30-93 were matched with age, gender and area of residency, and followed from 1 January 1997 to 31 December 2013. Baseline information was collected with questionnaires 1997 and follow-up register data from the national discharge registry Finnish Institute for Health and Welfare. Data included diagnoses from outpatient care and day surgery of specialised health care, and data from inpatient care of specialised and primary health care. We included all main diagnoses that had at minimum 200 events and number of diagnoses based on their common appearance with adult asthma.
RESULTS
RESULTS
The mean follow-up time varied between 14.2 and 15.1 years, and age at the time of enrolment was 53.9 years for subjects without asthma and 54.4 years for patients with asthma. Chronic obstructive pulmonary disease was 10 times more common among asthmatics. Risk of acute rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis and vocal cord dysfunction was fourfold and risk of pneumonia, and chronic rhinosinusitis was 2.5 times more common among asthmatics. Sleep apnoea, gastro-oesophageal reflux disease, diabetes, allergic rhinitis and dysfunctional breathing were twofold and cataract nearly twofold higher in the asthmatic group. Adult asthma was also significantly associated with musculoskeletal diseases, incontinence and bronchiectasis.
CONCLUSIONS
CONCLUSIONS
The most common and most severe comorbidity of adult asthma in this study was chronic obstructive pulmonary disease. Other common comorbidities of adult asthma include acute rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, allergic rhinitis, dysfunctional breathing, diabetes, pneumonia, sleep apnoea and gastro-oesophageal reflux disease.
Identifiants
pubmed: 38485249
pii: 11/1/e001959
doi: 10.1136/bmjresp-2023-001959
pmc: PMC10941122
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: Sanna Toppila-Salmi reports consultancies for ALK-Abelló, AstraZeneca, ERT, GSK, Novartis, Sanofi, and Roche Products outside the submitted work, as well as grant of GSK outside the submitted work. All other authors declare no conflicts of interest.
Références
Yonsei Med J. 2015 Nov;56(6):1663-70
pubmed: 26446652
Diabetes Metab Res Rev. 2019 Jan;35(1):e3073
pubmed: 30209868
Respiration. 2017;94(3):299-311
pubmed: 28738364
Lancet. 2022 Jun 11;399(10342):2227-2242
pubmed: 35533707
Semin Arthritis Rheum. 2020 Oct;50(5):968-976
pubmed: 32906033
Allergy. 2019 Dec;74(12):2406-2416
pubmed: 31269237
Mediators Inflamm. 2015;2015:819194
pubmed: 26783384
Clin Exp Allergy. 2022 Jul;52(7):868-877
pubmed: 35132702
Allergy. 2018 Jul;73(7):1479-1488
pubmed: 29461632
J Allergy Clin Immunol Pract. 2021 Nov;9(11):3877-3884
pubmed: 34506967
Front Pediatr. 2019 Jun 18;7:246
pubmed: 31275909
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1345-1357
pubmed: 31841642
Mediators Inflamm. 2016;2016:3690628
pubmed: 27212806
Allergy. 2018 Feb;73(2):284-294
pubmed: 28722758
J Allergy Clin Immunol Pract. 2020 Nov - Dec;8(10):3455-3465.e13
pubmed: 32679349
BMC Pulm Med. 2021 Feb 16;21(1):59
pubmed: 33593334
J Asthma Allergy. 2022 Feb 18;15:231-247
pubmed: 35210789
J Asthma Allergy. 2018 Aug 29;11:193-204
pubmed: 30214247
ERJ Open Res. 2020 Mar 23;6(1):
pubmed: 32211439
Int J Chron Obstruct Pulmon Dis. 2021 Jun 17;16:1783-1799
pubmed: 34168440
Ann Saudi Med. 2017 Mar-Apr;37(2):99-105
pubmed: 28377538
Aust Fam Physician. 2015 Aug;44(8):554-7
pubmed: 26510141
Ann Allergy Asthma Immunol. 2018 Nov;121(5):604-612.e3
pubmed: 30092266
Lancet. 2018 Feb 24;391(10122):783-800
pubmed: 29273246
Arch Dermatol Res. 2022 Aug;314(6):593-603
pubmed: 34100126
Phys Ther. 2021 Mar 3;101(3):
pubmed: 33351935
Curr Opin Pulm Med. 2020 Jan;26(1):47-55
pubmed: 31644439
Med Sci (Basel). 2019 Mar 27;7(4):
pubmed: 30934800
J Allergy Clin Immunol Pract. 2024 Jan;12(1):135-145.e9
pubmed: 37797715
Medicine (Baltimore). 2016 May;95(22):e3459
pubmed: 27258489
Respir Res. 2019 Oct 23;20(1):229
pubmed: 31647021
Med Clin North Am. 2020 Jan;104(1):95-108
pubmed: 31757240